Featured Research

from universities, journals, and other organizations

Continuing uncertainties surround anti-influenza drug

Date:
January 18, 2012
Source:
Wiley-Blackwell
Summary:
Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages of clinical trial data and documents used in the process of licensing oseltamivir (Tamiflu) by national authorities, a team of researchers has raised critical questions about how well the drug works and about its reported safety profile.

Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages of clinical trial data and documents used in the process of licensing oseltamivir (Tamiflu) by national authorities, a team of researchers has raised critical questions about how well the drug works and about its reported safety profile.

The new analysis shows inconsistencies with published reports, and describes possible under-reporting of drug-related side-effects in some published trial reports. While the drug did reduce the time to first alleviation of symptoms by an average of 21 hours, it did not reduce the number of people who went on to need hospital treatment. Results from the reanalysis of data also raise questions about how the drug works as an influenza virus inhibitor.

These finding are published in The Cochrane Library by an international team of researchers from Italy, Australia, USA, UK and Japan. It was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme.

In line with World Health Organization (WHO) recommendations made in 2002, governments around the world have spent billions of dollars stockpiling neuraminidase inhibitors such as oseltamivir and zanamivir (Relenza). The agents' proposed mode of action is to limit the proliferation of viruses within an infected person, which in turn reduce the duration of a person's symptoms, and consequently reduce the chances of passing the disease to another person.

Led by Dr Tom Jefferson, a Cochrane review author and independent epidemiologist based in Rome, Italy, a team of researchers have obtained and analysed data on antiviral drugs, much of which has never been published, and evaluated the evidence that lay behind some of the statements. This latest Cochrane review focused primarily on oseltamivir because it is a commonly used and stockpiled drug and is on the list of WHO essential drugs. The Cochrane team were reluctant to base their research on the trials that have been published in scientific journals, because while many trials have been conducted around the world, only a few have been published.

"We identified that a large number of studies, including data from 60% of the people who have been involved in randomised, placebo-controlled phase III treatment trials of oseltamivir have never been published. This includes the biggest treatment trial ever undertaken on oseltamivir that on its own included just over 1,400 people of all ages," says Jefferson. "We are concerned that these data remain unavailable for scrutiny by the scientific community."

Although the team were able to access thousands of pages of data provided to national regulatory agencies and other bodies, they were only able to access a proportion of the data they needed to evaluate fully the effects of oseltamivir, despite requests to the drug's manufacturer, Roche.

When the team compared published data with the more complete unpublished trial records, they found inconsistencies in the published record of the trials. For example, while unpublished trial reports mentioned serious adverse events (some even classified as possibly related to oseltamivir), one of the two most cited publications makes no mention of such effects, and the other states ." .. there were no drug-related serious adverse events."

Jefferson and colleagues also found disparities in the numbers of influenza-infected people reported to be present in the treatment versus control groups of oseltamivir trials. The researchers believe that this imbalance may be caused by oseltamivir affecting antibody production. "The disparity is important because in oseltamivir trials, primary efficacy outcomes were analyzed on the influenza infected subpopulation, but it is not clear that these groups were in fact comparable," says Jefferson.

The researchers conclude that there is an urgent need for independent research on both of these drugs. There is continuing uncertainty about their effects beyond the initial reduction in symptoms, mainly because full access to the data needed has still not been provided. "We believe that until more is known about the mode of action of neuraminidase inhibitors health professionals, patients and other decision makers need to reflect on the findings of this review before making any decision about the use of the drug," concluded Jefferson.

Also published in this issue of The Cochrane Library is an updated systematic review of neuraminidase inhibitors for children only ('Neuraminidase inhibitors for preventing and treating influenza in children' by Wang et al). Dr David Tovey, Editor in Chief of The Cochrane Library notes that "This review uses more standard review methods and only evaluates published studies. The two reviews therefore use different methods and this leads to differences regarding their findings, but some results are broadly similar to those presented in the review by Jefferson et al."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews, 2011; 12: CD008965 DOI: 10.1002/14651858.CD008965.pub2

Cite This Page:

Wiley-Blackwell. "Continuing uncertainties surround anti-influenza drug." ScienceDaily. ScienceDaily, 18 January 2012. <www.sciencedaily.com/releases/2012/01/120118111021.htm>.
Wiley-Blackwell. (2012, January 18). Continuing uncertainties surround anti-influenza drug. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2012/01/120118111021.htm
Wiley-Blackwell. "Continuing uncertainties surround anti-influenza drug." ScienceDaily. www.sciencedaily.com/releases/2012/01/120118111021.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Effects of Tamiflu Still Uncertain, Warn Experts, as Roche Continues to Withhold Key Trial Data, According to New Report

Jan. 18, 2012 Two years after pharmaceutical giant Roche promised the British Medical Journal it would release key Tamiflu trial data for independent scrutiny, the safety and effectiveness of this anti-influenza ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins